THE PREVALENCE AND CLINICAL CHARACTERISTICS OF CYSTIC FIBROSIS ARTHROPATHY

囊性纤维化关节病的患病率和临床特征

基本信息

  • 批准号:
    6120776
  • 负责人:
  • 金额:
    $ 3.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-12-01 至 1999-11-30
  • 项目状态:
    已结题

项目摘要

A prospective study of the prevalence, incidence, clinical characteristics, prognostic features, and pathologic description of cystic fibrosis arthropathy (CFA). CFA is characterized by recurrent, often painful bouts of mono-or polyarthritis. Many patients also manifest an erythema-nodosum-like rash, or in a few cases, purpuric skin lesions. The flares of joint inflammation last from one day to several weeks. Some patients with CFA progress to a chronic arthritis that can be quite debilitating. The appropriate treatment of CFA is not known and has not been studied in a large prospective study. The study is being performed simultaneously at Children's Hospital and The Massachusetts General Hospital as a combined effort of the Rheumatology Departments and Cystic Fibrosis Centers at each institution. The study entails screening for the presence of CFA with a questionnaire and follow-up medical chart review, physical exam, laboratory tests and selective radiographs. The study seeks to advance both the clinical and basic scientific knowledge of CFA and possibly gain insight into possible preventive or treatment measures.
一项前瞻性研究的患病率,发病率,临床 特征、预后特征和病理描述 囊性纤维化关节病(CFA)。CFA的特点是反复发作, 经常是疼痛的单发或多发性关节炎。许多患者也 出现结节性皮疹,或在少数情况下,紫癜 皮肤损伤关节炎的发作持续一天到 几个星期。一些CFA患者进展为慢性关节炎 这会让人很虚弱对CFA的适当处理不是 已知,尚未在大型前瞻性研究中进行研究。研究 正在儿童医院和 马萨诸塞州总医院作为一个联合的努力, 部门和囊性纤维化中心在每个机构。研究 需要通过问卷调查筛选CFA的存在, 随访病历审查、体格检查、实验室检查和 选择性X光片。该研究旨在促进临床和 CFA的基本科学知识,并可能深入了解 可能的预防或治疗措施。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT SUNDEL其他文献

ROBERT SUNDEL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT SUNDEL', 18)}}的其他基金

Blood cell activity in Kawasaki Disease
川崎病的血细胞活性
  • 批准号:
    6975180
  • 财政年份:
    2004
  • 资助金额:
    $ 3.04万
  • 项目类别:
THE PREVALENCE AND CLINICAL CHARACTERISTICS OF CYSTIC FIBROSIS ARTHROPATHY
囊性纤维化关节病的患病率和临床特征
  • 批准号:
    6220556
  • 财政年份:
    1998
  • 资助金额:
    $ 3.04万
  • 项目类别:
TREATMENT OF KAWASAKI DISEASE--PULSE IV METHYLPREDNISOLONE VS IVIG
川崎病的治疗--PULSE IV甲泼尼龙VS IVIG
  • 批准号:
    6120816
  • 财政年份:
    1998
  • 资助金额:
    $ 3.04万
  • 项目类别:
THE PREVALENCE AND CLINICAL CHARACTERISTICS OF CYSTIC FIBROSIS ARTHROPATHY
囊性纤维化关节病的患病率和临床特征
  • 批准号:
    6281395
  • 财政年份:
    1997
  • 资助金额:
    $ 3.04万
  • 项目类别:
THE PREVALENCE AND CLINICAL CHARACTERISTICS OF CYSTIC FIBROSIS ARTHROPATHY
囊性纤维化关节病的患病率和临床特征
  • 批准号:
    6251893
  • 财政年份:
    1997
  • 资助金额:
    $ 3.04万
  • 项目类别:
TREATMENT OF KAWASAKI DISEASE--PULSE IV METHYLPREDNISOLONE VS IVIG
川崎病的治疗--PULSE IV甲泼尼龙VS IVIG
  • 批准号:
    6281435
  • 财政年份:
    1997
  • 资助金额:
    $ 3.04万
  • 项目类别:
THE PREVALENCE AND CLINICAL CHARACTERISTICS OF CYSTIC FIBROSIS ARTHROPATHY
囊性纤维化关节病的患病率和临床特征
  • 批准号:
    5223796
  • 财政年份:
  • 资助金额:
    $ 3.04万
  • 项目类别:
THE PREVALENCE AND CLINICAL CHARACTERISTICS OF CYSTIC FIBROSIS ARTHROPATHY
囊性纤维化关节病的患病率和临床特征
  • 批准号:
    6308988
  • 财政年份:
  • 资助金额:
    $ 3.04万
  • 项目类别:

相似海外基金

Rapid detection of Pseudomonas aeruginosa in people with cystic fibrosis
快速检测囊性纤维化患者中的铜绿假单胞菌
  • 批准号:
    10103495
  • 财政年份:
    2024
  • 资助金额:
    $ 3.04万
  • 项目类别:
    Collaborative R&D
Rational optimization of combinatorial therapies for the treatment of rare cystic fibrosis variants
合理优化治疗罕见囊性纤维化变异的组合疗法
  • 批准号:
    10736732
  • 财政年份:
    2023
  • 资助金额:
    $ 3.04万
  • 项目类别:
Pulmonary delivery of base editors for gene therapy of cystic fibrosis with nonsense mutations
肺部递送碱基编辑器用于无义突变囊性纤维化的基因治疗
  • 批准号:
    488681
  • 财政年份:
    2023
  • 资助金额:
    $ 3.04万
  • 项目类别:
    Operating Grants
Analysis of synthetic derivatives with reduced lipophilicity as candidate potentiators towards better treatment alternatives for Cystic Fibrosis
分析亲脂性降低的合成衍生物作为候选增效剂,以获得更好的囊性纤维化治疗替代方案
  • 批准号:
    481159
  • 财政年份:
    2023
  • 资助金额:
    $ 3.04万
  • 项目类别:
Developing Gene Editing Therapeutics, Biodegradable Polymeric Delivery Vehicles, and High-throughput Platforms for the Treatment of Cystic Fibrosis
开发用于治疗囊性纤维化的基因编辑疗法、可生物降解的聚合物递送载体和高通量平台
  • 批准号:
    10836095
  • 财政年份:
    2023
  • 资助金额:
    $ 3.04万
  • 项目类别:
A Ginsenoside TMEM16A Potentiator for Cystic Fibrosis
人参皂苷 TMEM16A 治疗囊性纤维化的增效剂
  • 批准号:
    10574384
  • 财政年份:
    2023
  • 资助金额:
    $ 3.04万
  • 项目类别:
Computationally-Inspired Design of Non-Viral Gene Delivery Vehicles for mRNA-Based Cystic Fibrosis Therapies
用于基于 mRNA 的囊性纤维化治疗的非病毒基因传递载体的计算启发设计
  • 批准号:
    10760605
  • 财政年份:
    2023
  • 资助金额:
    $ 3.04万
  • 项目类别:
The role of anaerobic microbiota in cystic fibrosis airway disease trajectory
厌氧微生物群在囊性纤维化气道疾病轨迹中的作用
  • 批准号:
    10716654
  • 财政年份:
    2023
  • 资助金额:
    $ 3.04万
  • 项目类别:
Health Outcomes of Parents with Cystic Fibrosis (HOPe:CF)
患有囊性纤维化的父母的健康结果 (HOPe:CF)
  • 批准号:
    10581321
  • 财政年份:
    2023
  • 资助金额:
    $ 3.04万
  • 项目类别:
Preparation for lung transplant discussions and decisions among people with cystic fibrosis
囊性纤维化患者肺移植讨论和决策的准备
  • 批准号:
    10657027
  • 财政年份:
    2023
  • 资助金额:
    $ 3.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了